Choice of conservative therapeutic modalities for hepatocellular carcinoma

Yasushi Shingai, Keijiro Ando, Yuji Kado, Mitsuru Yasunaga, Hiroshi Nawata, Keiki Ogino, Kiwamu Okita, Tadayoshi Takemoto

Research output: Contribution to journalArticle

Abstract

309 patients with hepatocellular carcinoma (HCC) were studied to discuss the efficacy of, and the appropriate selection of conservative therapeutic modalities for HCC. These modalities included partial hepatectomy (22 cases), transcatheter arterial embolization (TAE) (35 cases) lipiodolization (32 cases), one-shot therapy (140 cases), and no or only systemic chemotherapy (80 cases). Eleven patients also underwent IFN-y therapy. And patients were stratified into 3 to 4 grades according to clinical stage (CS), tumor stage (TS) and portal invasion (Vp). Active treatments such as TAE, lipiodolization and one-shot therapy are effective in CS I to II, TS I to II and Vp 0 to 3. On the other hand, these treatments are of little prospect of life-prolongation in CS III, TS III and/or Vp 4. IFN-y can be expected as an appropriate systemic treatment because of the elevated NK activity following its administration.

Original languageEnglish
Pages (from-to)1568-1577
Number of pages10
JournalKanzo
Volume27
Issue number11
DOIs
Publication statusPublished - 1986
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Life Support Care
Neoplasms
Hepatectomy
Drug Therapy

ASJC Scopus subject areas

  • Hepatology

Cite this

Shingai, Y., Ando, K., Kado, Y., Yasunaga, M., Nawata, H., Ogino, K., ... Takemoto, T. (1986). Choice of conservative therapeutic modalities for hepatocellular carcinoma. Kanzo, 27(11), 1568-1577. https://doi.org/10.2957/kanzo.27.1568

Choice of conservative therapeutic modalities for hepatocellular carcinoma. / Shingai, Yasushi; Ando, Keijiro; Kado, Yuji; Yasunaga, Mitsuru; Nawata, Hiroshi; Ogino, Keiki; Okita, Kiwamu; Takemoto, Tadayoshi.

In: Kanzo, Vol. 27, No. 11, 1986, p. 1568-1577.

Research output: Contribution to journalArticle

Shingai, Y, Ando, K, Kado, Y, Yasunaga, M, Nawata, H, Ogino, K, Okita, K & Takemoto, T 1986, 'Choice of conservative therapeutic modalities for hepatocellular carcinoma', Kanzo, vol. 27, no. 11, pp. 1568-1577. https://doi.org/10.2957/kanzo.27.1568
Shingai Y, Ando K, Kado Y, Yasunaga M, Nawata H, Ogino K et al. Choice of conservative therapeutic modalities for hepatocellular carcinoma. Kanzo. 1986;27(11):1568-1577. https://doi.org/10.2957/kanzo.27.1568
Shingai, Yasushi ; Ando, Keijiro ; Kado, Yuji ; Yasunaga, Mitsuru ; Nawata, Hiroshi ; Ogino, Keiki ; Okita, Kiwamu ; Takemoto, Tadayoshi. / Choice of conservative therapeutic modalities for hepatocellular carcinoma. In: Kanzo. 1986 ; Vol. 27, No. 11. pp. 1568-1577.
@article{f769237598e9441eb1964608dd95f9ca,
title = "Choice of conservative therapeutic modalities for hepatocellular carcinoma",
abstract = "309 patients with hepatocellular carcinoma (HCC) were studied to discuss the efficacy of, and the appropriate selection of conservative therapeutic modalities for HCC. These modalities included partial hepatectomy (22 cases), transcatheter arterial embolization (TAE) (35 cases) lipiodolization (32 cases), one-shot therapy (140 cases), and no or only systemic chemotherapy (80 cases). Eleven patients also underwent IFN-y therapy. And patients were stratified into 3 to 4 grades according to clinical stage (CS), tumor stage (TS) and portal invasion (Vp). Active treatments such as TAE, lipiodolization and one-shot therapy are effective in CS I to II, TS I to II and Vp 0 to 3. On the other hand, these treatments are of little prospect of life-prolongation in CS III, TS III and/or Vp 4. IFN-y can be expected as an appropriate systemic treatment because of the elevated NK activity following its administration.",
author = "Yasushi Shingai and Keijiro Ando and Yuji Kado and Mitsuru Yasunaga and Hiroshi Nawata and Keiki Ogino and Kiwamu Okita and Tadayoshi Takemoto",
year = "1986",
doi = "10.2957/kanzo.27.1568",
language = "English",
volume = "27",
pages = "1568--1577",
journal = "Acta Hepatologica Japonica",
issn = "0451-4203",
publisher = "Japan Society of Hepatology",
number = "11",

}

TY - JOUR

T1 - Choice of conservative therapeutic modalities for hepatocellular carcinoma

AU - Shingai, Yasushi

AU - Ando, Keijiro

AU - Kado, Yuji

AU - Yasunaga, Mitsuru

AU - Nawata, Hiroshi

AU - Ogino, Keiki

AU - Okita, Kiwamu

AU - Takemoto, Tadayoshi

PY - 1986

Y1 - 1986

N2 - 309 patients with hepatocellular carcinoma (HCC) were studied to discuss the efficacy of, and the appropriate selection of conservative therapeutic modalities for HCC. These modalities included partial hepatectomy (22 cases), transcatheter arterial embolization (TAE) (35 cases) lipiodolization (32 cases), one-shot therapy (140 cases), and no or only systemic chemotherapy (80 cases). Eleven patients also underwent IFN-y therapy. And patients were stratified into 3 to 4 grades according to clinical stage (CS), tumor stage (TS) and portal invasion (Vp). Active treatments such as TAE, lipiodolization and one-shot therapy are effective in CS I to II, TS I to II and Vp 0 to 3. On the other hand, these treatments are of little prospect of life-prolongation in CS III, TS III and/or Vp 4. IFN-y can be expected as an appropriate systemic treatment because of the elevated NK activity following its administration.

AB - 309 patients with hepatocellular carcinoma (HCC) were studied to discuss the efficacy of, and the appropriate selection of conservative therapeutic modalities for HCC. These modalities included partial hepatectomy (22 cases), transcatheter arterial embolization (TAE) (35 cases) lipiodolization (32 cases), one-shot therapy (140 cases), and no or only systemic chemotherapy (80 cases). Eleven patients also underwent IFN-y therapy. And patients were stratified into 3 to 4 grades according to clinical stage (CS), tumor stage (TS) and portal invasion (Vp). Active treatments such as TAE, lipiodolization and one-shot therapy are effective in CS I to II, TS I to II and Vp 0 to 3. On the other hand, these treatments are of little prospect of life-prolongation in CS III, TS III and/or Vp 4. IFN-y can be expected as an appropriate systemic treatment because of the elevated NK activity following its administration.

UR - http://www.scopus.com/inward/record.url?scp=0022840280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022840280&partnerID=8YFLogxK

U2 - 10.2957/kanzo.27.1568

DO - 10.2957/kanzo.27.1568

M3 - Article

AN - SCOPUS:0022840280

VL - 27

SP - 1568

EP - 1577

JO - Acta Hepatologica Japonica

JF - Acta Hepatologica Japonica

SN - 0451-4203

IS - 11

ER -